Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

9:30pm IST
Change (% chg)

0.50kr (+0.27%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sobi raises outlook as Q3 core profit beats expectations
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Swedish Orphan Biovitrum Ab (Publ) :Swedish orphan biovitrum q3 ‍ebita was sek 536 m (282)​.Swedish orphan biovitrum says ‍sobi now expects total revenues for full year to be in range of sek 6,300 to 6,400 m (6,100-6,200)​.Swedish orphan biovitrum says ‍gross margin is expected to be around 70 per cent​.Swedish orphan biovitrum q3 ‍total revenue was sek 1,601 m​.Swedish orphan biovitrum says ‍now expects ebita for full year to be in range of sek 1,900 to 2,000 m (1,700-1,800)​.Swedish orphan biovitrum says ‍growth strategy has been designed to capitalise on substantial potential in haemophilia​.Swedish orphan biovitrum says ‍based on this solid platform we will further balance business with a broader specialty care portfolio to ensure a sustainable company in both short and long-term​.Swedish orphan biovitrum says to decentralise decision making towards the country organisations, resource allocation to support this strategic initiative will be reflected accordingly‍​.Swedish orphan biovitrum says we are rebalancing our geographical footprint in our existing markets by, among other things, scaling and developing our north american franchise‍​.Swedish orphan biovitrum says the strengthening of our late stage research and development pipeline is another key area of focus going forward‍​.Reuters poll: sobi q3 ebita was seen at 509 million sek, revenues at 1,636 million.  Full Article

Sobi's CEO divests a portion of shares
Monday, 8 Aug 2016 

: Swedish Orphan Biovitrum (SOBI) says: . CEO Geoffrey McDonough has divested 300,000 of shares he holds in company. .The sale was made for personal financial reasons. After the transaction, McDonough will hold a total of 347,948 shares in the company..  Full Article

Sobi says to repurchase shares
Friday, 15 Jul 2016 

Swedish Orphan Biovitrum Publ AB (SOBI) : Says the board of directors exercises its authorisation for repurchase of shares to secure the company's commitments under the incentive programme . Says repurchase of the class C shares may be effected during the period 15 July - 27 September 2016 .Says the class C shares will, following the repurchase, be converted to common shares.  Full Article

SOBI Q2 EBITA above forecast
Friday, 15 Jul 2016 

Swedish Orphan Biovitrum : Q2 total revenue was sek 1,469 mln (764) . Q2 EBITA was sek 550 mln (74) . Q2 revenues include a sek 386 mln one-time credit from biogen triggered by first commercial sales of alprolix . Q2 gross margin was 72 per cent (63) . Outlook 2016 unchanged .Reuters poll: Sobi Q2 EBITA was seen at sek 435 mln, revenues at 1,317 mln.  Full Article

Pharming Group amends Ruconest distribution agreement with Sobi
Thursday, 14 Jul 2016 

Pharming Group NV : Pharming amends ruconest distribution agreement with Sobi . Pharming to directly commercialise Ruconest in 21 additional Western European, North African and Middle-Eastern markets .Pharming will expand current small European team of experienced hae marketing and medical affairs specialists.  Full Article